Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits

Background and Purpose— Transcranial near-infrared laser therapy (TLT) is currently under investigation in a pivotal clinical trial that excludes thrombolytic therapy. To determine if combining tissue plasminogen activator (tPA; Alteplase) and TLT is safe, this study assessed the safety profile of TLT administered alone and in combination with Alteplase. The purpose for this study is to determine if the combination of TLT and thrombolysis should be investigated further in a human clinical trial. Methods— We determined whether postembolization treatment with TLT in the absence or presence of tPA would affect measures of hemorrhage or survival after large clot embolism-induced strokes in New Zealand white rabbits. Results— TLT did not significantly alter hemorrhage incidence after embolization, but there was a trend for a modest reduction of hemorrhage volume (by 65%) in the TLT-treated group compared with controls. Intravenous administration of tPA, using an optimized dosing regimen, significantly increased hemorrhage incidence by 160%. The tPA-induced increase in hemorrhage incidence was not significantly affected by TLT, although there was a 30% decrease in hemorrhage incidence in combination-treated rabbits. There was no effect of TLT on hemorrhage volume measured in tPA-treated rabbits and no effect of any treatment on 24-hour survival rate. Conclusion— In the embolism model, TLT administration did not affect the tPA-induced increase in hemorrhage incidence. TLT may be administered safely either alone or in combination with tPA because neither treatment affected hemorrhage incidence or volume. Our results support the study of TLT in combination with Alteplase in patients with stroke.

[1]  P. Lapchak,et al.  Advances in hemorrhagic stroke therapy: conventional and novel approaches , 2007, Expert opinion on emerging drugs.

[2]  P. Lyden.  Further randomized controlled trials of tPA within 3 hours are required-not! , 2001, Stroke.

[3]  P. Lyden,et al.  Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. , 2006, Vascular pharmacology.

[4]  Kunio Awazu,et al.  Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue , 2002, Neuroscience Letters.

[5]  Rina Das,et al.  Clinical and experimental applications of NIR-LED photobiomodulation. , 2006, Photomedicine and laser surgery.

[6]  P. Lyden,et al.  Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model , 2001, Stroke.

[7]  G. Rosenberg.  Matrix metalloproteinases in brain injury. , 1995, Journal of neurotrauma.

[8]  Jr. MD O. Castro-e-Silva,et al.  Spectral response for laser enhancement in hepatic regeneration for hepatectomized rats , 2003, Lasers in surgery and medicine.

[9]  William G. Stetler-Stevenson,et al.  Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window , 1995, Brain Research.

[10]  P. Lyden,et al.  Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. , 1990, Stroke.

[11]  Noel T. Whelan,et al.  Therapeutic photobiomodulation for methanol-induced retinal toxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Lapchak,et al.  Reducing Bleeding Complications After Thrombolytic Therapy for Stroke , 2001, CNS drugs.

[13]  P. Lyden,et al.  Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. , 1991, Stroke.

[14]  P. Lapchak,et al.  Transcranial Infrared Laser Therapy Improves Clinical Rating Scores After Embolic Strokes in Rabbits , 2004, Stroke.

[15]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[16]  P. Lapchak.  Tumor necrosis factor-α is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits , 2007, Brain Research.

[17]  P. Lapchak,et al.  Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits , 2004, Experimental Neurology.

[18]  P. Lapchak,et al.  Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: An extended therapeutic window study using continuous and pulse frequency delivery modes , 2007, Neuroscience.

[19]  W. P. Van De Merwe,et al.  Low power laser irradiation alters the rate of regeneration of the rat facial nerve , 1993, Lasers in surgery and medicine.

[20]  Jieli Chen,et al.  Low-Level Laser Therapy Applied Transcranially to Rats After Induction of Stroke Significantly Reduces Long-Term Neurological Deficits , 2006, Stroke.

[21]  P. Lapchak.  3α-OL-5-β-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: Synergism with tissue plasminogen activator , 2006, Experimental Neurology.

[22]  Marc Fisher,et al.  Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.

[23]  B. Friedman,et al.  Stroke-Evoked Angiogenesis Results in a Transient Population of Microvessels , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  P. Lyden.  Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms? , 2006, Nature Clinical Practice Cardiovascular Medicine.

[25]  P. Lapchak,et al.  Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator , 2002, Stroke.

[26]  Amir Oron,et al.  Transcranial application of low‐energy laser irradiation improves neurological deficits in rats following acute stroke , 2006, Lasers in surgery and medicine.

[27]  P. Lapchak,et al.  The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke , 2002, Stroke.

[28]  J. Zivin.  Thrombolytic stroke therapy , 1999, Neurology.

[29]  G. Albers,et al.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.

[30]  P. Lapchak,et al.  Advances in ischemic stroke treatment: neuroprotective and combination therapies , 2007, Expert opinion on emerging drugs.

[31]  S. Davis,et al.  Alteplase for acute stroke revisited: the first 10 years , 2006, The Lancet Neurology.

[32]  P. Lapchak.  Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment , 2002, Current neurology and neuroscience reports.

[33]  P. Lapchak,et al.  Neuroprotective Effects of the Spin Trap Agent Disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) in a Rabbit Small Clot Embolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator , 2002, Stroke.

[34]  S Nioka,et al.  Study of near infrared technology for intracranial hematoma detection. , 2000, Journal of biomedical optics.

[35]  E. Lo,et al.  Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases , 2002, Journal of neuroscience research.

[36]  U. Oron,et al.  Low-energy laser irradiation enhances de novo protein synthesis via its effects on translation-regulatory proteins in skeletal muscle myoblasts. , 2003, Biochimica et biophysica acta.

[37]  U. Oron,et al.  Promotion of angiogenesis by low energy laser irradiation. , 2002, Antioxidants & redox signaling.

[38]  Uri Oron,et al.  Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis , 2006, Lasers in surgery and medicine.

[39]  A. Gearing,et al.  Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures , 2001, Brain Research.

[40]  G. Press,et al.  Tissue plasminogen activator‐mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits , 1989, Neurology.

[41]  U. Oron,et al.  Impact of low level laser irradiation on infarct size in the rat following myocardial infarction. , 2001, International journal of cardiology.

[42]  J. Rothrock,et al.  Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. , 1987, Archives of neurology.

[43]  T. Osborn,et al.  Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies. , 1999, Annals of emergency medicine.